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S U M M A R Y
Dr Thato Mosidi never expected to be diagnosed with tuberculosis (TB), despite widely prevalent
exposure and very limited infection control measures. The life-threatening diagnosis of primary
extensively drug-resistant TB (XDR-TB) came as an even greater shock. The inconvenient truth is that,
rather than being protected, Dr Mosidi and thousands of her healthcare colleagues are at an increased
risk of TB and especially drug-resistant TB. In this viewpoint paper we debunk the widely held false belief
that healthcare workers are somehow immune to TB disease (TB-proof) and explore some of the key
factors contributing to the pervasive stigmatization and subsequent non-disclosure of occupational TB.
Our front-line workers are some of the ﬁrst to suffer the consequences of a progressively more resistant
and fatal TB epidemic, and urgent interventions are needed to ensure the safety and continued
availability of these precious healthcare resources. These include the rapid development and scale-up of
improved diagnostic and treatment options, strengthened infection control measures, and focused
interventions to tackle stigma and discrimination in all its forms. We call our colleagues to action to
protect themselves and those they care for.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-SA license (http://creativecommons.org/licenses/by-
nc-sa/4.0/).
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Tuberculosis (TB) in all its forms is a major occupational hazard
for healthcare workers (HCWs) worldwide.1,2 The transmission of* Corresponding author. Tel.: +27 72 6992473.
E-mail address: vuzumsi@gmail.com (A. von Delft).
http://dx.doi.org/10.1016/j.ijid.2014.12.003
1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-sa/4.0/).drug-sensitive and drug-resistant (DR) strains of Mycobacterium
tuberculosis occurs through infected droplets aerosolized by
patients with active pulmonary TB. The transmission risk to HCWs
is highest when patients have unrecognized TB or are receiving
inappropriate treatment.3 However many other factors inﬂuence
the risk of transmission and progression to active disease,
including healthcare setting, occupational category, individual
susceptibility/immune status, and the adequacy of TB infectionciety for Infectious Diseases. This is an open access article under the CC BY-NC-SA
A. von Delft et al. / International Journal of Infectious Diseases 32 (2015) 147–151148control (IC) measures. In recent years there have been alarming
increases in drug-resistant TB in some populations, and multi-
drug-resistant TB (MDR-TB: resistance to at least rifampin and
isoniazid) and extensively drug-resistant TB (XDR-TB: as for
MDR-TB plus resistance to a quinolone and one other injectable
drug) together pose a colossal yet overlooked public health threat.
We relate some personal experiences of HCWs who have been
affected by TB, explore factors that increase the risk, and discuss
the lack of an effective global response to the growing problem of
DR-TB.4
2. Not TB-proof after all: a healthcare worker’s encounter with
XDR-TB
‘‘There’s blood in the basin’’ Dr Thato Mosidi told her husband,
while trying to suppress the urge to cough again. Although she had
never had TB, she knew the symptoms. Driving to the consultation
with her physician in Johannesburg, South Africa, she was calm,
secure in the knowledge that TB was curable and that as a healthy
young physician, there was little to worry about. A few weeks later
her physician called to break the terrible news: she had XDR-TB. It
was not until this moment that she realized the gravity of her
condition. ‘‘I could die’’ she told her husband, weeping as she hung
up the phone.
This is the typical response of a HCW diagnosed with DR-TB.
What follows in the long months to years of therapy, is a slow
realization of how this diagnosis changes one’s life irrevocably: the
debilitating adverse effects associated with treatment, stigma in
the community, but also from colleagues and even family, the risk
of transmission to your loved ones, ﬁnancial hardship, and career
limitations. And the lingering question: ‘‘I’m supposed to be safe,
what did I do wrong?’’
3. Treating our way to incurable TB
Why would a HCW worry about dying from a disease that is
considered curable? Despite notable gains in increasing access to
treatment, 1.5 million people still lose their lives to TB every year.4
In addition, the World Health Organization (WHO) has estimated
that there are 3 million incident TB cases that go undiagnosed and
untreated every year, perpetuating transmission. For those who
are diagnosed with TB, presentation to healthcare is often delayed,
with an average 2-month interval between symptom onset and the
start of effective therapy.5 Ongoing transmission is also facilitated
by the lack of a rapid, point-of-care test to conﬁrm the diagnosis of
TB, and a rapid follow-on test for the speciﬁc drug-susceptibility of
the bacteria.
Increasingly, our ability to cure TB is under threat from highly
transmissible DR-TB strains.6 In 2013, an estimated 480 000
people developed MDR-TB globally; however less than 30% of
cases were detected, notiﬁed, and appropriately managed by TB
programmes.4 Tugela Ferry (a rural community in South Africa)
made international headlines in 2006, when a cluster of XDR-TB
patients with unprecedented nosocomial transmission and
mortality rates was described,7 emphasizing the importance
of infection control and well-functioning TB control pro-
grammes.8 Since then, the global ‘emergency response’ has
been decidedly underwhelming: XDR-TB has been reported in
100 countries, every country where extensive screening has
been undertaken.4 Deﬁnitions of DR-TB beyond XDR are
controversial, but the reality is that many of these patients
suffer from incurable TB. Well-intentioned, yet woefully inade-
quate attempts at treating them have resulted in strains
resistant to every TB drug tested.9–114. What does it mean if we can’t treat TB?
Multiple treatment-related factors are implicated in the
creation of increasingly drug-resistant TB strains,12,13 but the
main driver of the global pandemic is underappreciated: the fact
that the spread of M. tuberculosis (and DR-TB) is airborne and we all
need to breathe! Primary person-to-person transmission now
accounts for up to three quarters of DR-TB cases.14,15
In the absence of a protective TB vaccine, the value of effective
treatment as prevention cannot be overstated.3 Unfortunately the
vast majority of MDR-TB patients do not have access to appropriate
treatment: only 20% of estimated MDR-TB cases started on second-
line treatment in 2013 globally.4 For XDR-TB the scenario is even
worse. A recent prospective cohort study in South Africa reported
that after 5 years of follow-up, only 11% of patients were cured or
had completed treatment. The remainder of the cohort either died
(73%) or failed treatment (10%). The median survival of patients
with XDR-TB who had failed treatment and were discharged back
home was almost 20 months. This is a matter of grave concern: the
prolonged transmission of essentially incurable TB amongst
families, the community, and at healthcare facilities.10 These
dismal outcomes may result in even greater delays in seeking care,
as communities perceive treatment of DR-TB as futile and the
diagnosis as a death sentence.
5. The burden of TB exposure in HCWs
Why did Dr Mosidi fall victim to DR-TB while believing that she
was at low risk of acquiring a serious occupational disease? Was
this transmission episode a rare example of failed TB infection
control measures? Or was she just unlucky and exposed at
random? Neither. The alarming reality is that she was led to
believe that she, and all of her ‘healthy’ colleagues, were somehow
immune to TB or ‘TB-proof’ – a phenomenon characterized by a
heightened awareness of the disease among others, but a low
perception of self-risk. An alternative explanation may be that the
HCW’s perception of risk is gradually eroded by habituation to the
risks of working in a TB-endemic setting.16
While many HCWs are rightfully afraid of catching TB from
their patients in crowded hospital wards and clinics, they develop
psychological defence and coping mechanisms to face work every
day. We frequently hear seniors say to younger trainees, ‘‘Why are
you wearing that (N95) mask? I have worked here for many years
and have never gotten TB.’’ Nervous laughter ensues, and the
trainee’s respirator is absent the next day. That attitude of ‘battle-
hardened’ invincibility often ﬁlters down to younger HCWs, who
internalize these reassuring but false beliefs. But as cases of
occupational TB grow, and occupational DR-TB is disclosed, this
tension between denial and recognition of danger continues to
grow.
A systematic review of TB incidence in low- and middle-income
countries estimated the annual risk of TB infection in HCWs to
range from 3.9% to 14.3% (with between 2.6% and 11.3%
attributable to occupational exposure).17 A subsequent meta-
analysis estimated that the average annual risk of developing TB
disease was three times higher (95% conﬁdence interval 2.43–3.51)
for HCWs (across all settings) compared to the general popula-
tion.18 A delay in DR-TB diagnosis, less effective treatment for DR-
TB, and longer periods of healthcare contact for DR-TB patients,
increase the potential for transmission of DR-TB strains to HCWs.
Accordingly, HCWs are up to six times more likely to be
hospitalized for DR-TB than the population they care for (incidence
rate ratio 5.46 for MDR and 6.28 for XDR).19 Furthermore, HCWs
with DR-TB are diagnosed late and have poor treatment outcomes,
even when HIV-uninfected.20,21
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Stigma, fed by a combination of fear and denial, aggravates
delays in diagnosis and treatment, and sustains an unspoken
culture of ‘don’t ask, don’t tell’.22 When HCWs contract TB and are
(eventually) diagnosed, they frequently seek treatment secretly.
They dread public disclosure of their TB diagnosis, fearing a
backlash from colleagues, who themselves are afraid of contracting
TB. Among TB patients, it has been shown that disclosure is more
likely to occur when the patient is assured that they will not be
stigmatized.23
HIV is the elephant in the room when discussing stigma and TB
in HCWs. In Sub-Saharan Africa, TB and HIV are inexorably linked
in the minds of many people.24,25 If a HCW discloses that they have
TB, the reaction of many colleagues is to wonder, or even openly
discuss, if that individual could be co-infected with HIV. The
psychological effort involved in concealing illness to avoid (valid
fears) of further discrimination can be detrimental.26 Therefore,
almost as a rule, they do not disclose their HIV status, even though
they are at an even greater risk of TB and could potentially reduce
this risk with the use of antiretrovirals, additional IC measures,
and/or alternative work placements.
Career implications of a TB diagnosis also play a role in
discouraging disclosure and driving stigma. Healthcare work in
developing countries is challenging, with generally low salaries
and poor working conditions.27Many HCWs are at the mercy of the
public sector and can be ﬁred or re-assigned if they complain about
working conditions. This prevents HCWs from disclosing their TB
diagnoses and advocating for safer working conditions, thus
fuelling the vicious cycles of misinformation, discrimination, and
unchecked TB transmission in health facilities. Migrant HCWs in
high income countries may also be reluctant to disclose a TB
diagnosis in the face of stigma and their limited entitlement to
sickness pay/social welfare due to restrictions on their immigra-
tion status.
7. Hope for new and improved treatment options
Thankfully Dr Mosidi (in stark contrast to 75% of her fellow
South Africans with XDR-TB), did not die. She culture-converted,
along with 48 out of 58 other pre-XDR and XDR-TB patients in the
same novel clinical access programme (Ndjeka, 45th Union
Conference, Late Breaker Presentation, 2014). This dramatic
difference can be attributed to access to two new drugs: linezolid,
a repurposed broad-spectrum Gram-positive antibiotic, and
bedaquiline, the ﬁrst new TB drug developed in 42 years.
Unfortunately neither drug is without controversy, with major
cost implications for TB programmes and a host of serious proven
(and potential) drug-related adverse effects.28–30 However for
patients with a potentially lethal disease, these are costs and risks
worth taking.
Delaying access to novel therapies can have dire consequences
for patients, but also for the healthcare workforce, as highlighted
not only by alarming HCW mortality rates, but also the high
prevalence of irreversible and career-ending side-effects, like
deafness.31,32 It is therefore crucially important to fast-track the
development of and access to rapid TB diagnostics, novel
compounds, and, most importantly, new drug combinations that
may slow the transmission of DR-TB by providing more rapidly
bactericidal therapy.3 These innovations could save lives and
protect those who care for patients. There is currently no effective
and accepted pre- or post-exposure prophylaxis for DR-TB.
Isoniazid preventative therapy (IPT) has limited evidence of
protection against DR-TB transmission, but data supporting the
long-term use of IPT are scarce.33 This is a major problem,
especially for HCWs living with HIV, who at present rely only onoptimized HIV care and where feasible (and status disclosed),
alternative work placement.
On a personal level, DR-TB treatment failure decimates family
and community structures. DR-TB sufferers live in fear of infecting
their loved ones and are often ostracized by their communities. The
currently available treatment regimens can be more debilitating
than the disease. In addition, for many DR-TB sufferers, the
impossible ‘choice’ between adherence and keeping food on their
families’ tables is a reality. Additional resources for new
preventative and curative therapies, improved patient support,
and prevention of household and community transmission of DR-
TB are urgently needed.
8. Safety ﬁrst: improving implementation of TB infection
control measures
How can Dr Mosidi and her colleagues claim back a safe
working environment? The pre- (and post-) antibiotic solution is
rigorous implementation of TB IC programmes. This goal is
achievable, even in countries with resource limitations.34 Unfor-
tunately the resources for and implementation of TB IC are often
poorest in countries with the greatest TB burden. Two recent South
African studies found less than 50% compliance with IC recom-
mendations35 and that 55% of HCWs did not wear personal
respiratory protective equipment when indicated.36
Improved access to information on TB infection risk has been
shown to inﬂuence HCWs IC practices and behaviours.37 Beha-
vioural change theories are valuable yet underutilized tools to help
change attitudes and practices.38 We need to learn from our HIV
colleagues: the personal touch matters. By sharing their stories,
occupational TB survivors like Dr Mosidi have not only helped
debunk the ‘TB-proof’ fallacy and raise much needed awareness
about the importance of TB IC, but have also mobilized resources to
address broader priorities such as access to new drugs and
improved patient support.39 In addition to addressing the issue of
occupational TB, improved IC measures have potential to avert a
broad range of nosocomial infections, with additional patient and
ﬁnancial beneﬁts.
The appalling Ebola virus disease (EVD) outbreak has been a
painful reminder of the frailty of our IC systems, and there are no
quick ﬁxes: administrative controls should allow for screening and
cohorting of symptomatic patients, surgical masks for coughing
patients, and access to rapid reliable diagnostics. These controls
should also include regular occupational TB screening, appropriate
support, employment security, and compensation for HCWs with
TB. Managers should be accountable for preventable nosocomial
spread of disease, with designated IC ofﬁcers at all facilities.
Pragmatic environmental measures such as ensuring adequate
natural and/or mechanical ventilation should be audited regularly.
Lastly, staff should be ﬁt-tested for N95 respirators and a reliable
supply of quality-assured respirators ensured.
The bulk of TB transmission both in the community and in
healthcare settings still occurs before an accurate diagnosis can be
made. The onus is on ensuring that TB IC measures are applied in all
high-risk settings so that healthcare facilities become known as
places of healing and safety, not death and contagion. At the same
time, patients and their loved ones should be engaged in efforts to
implement TB IC and embraced as part of the solution, rather than
the problem.
9. When protection is not negotiable
In most resource-poor settings, HCWs are in short supply and
should be considered an extremely valuable national asset. In
practice, HCWs appear expendable, at least in the minds of
policymakers, who consistently fail to allocate sufﬁcient resources
Photo 1. Four occupational drug-resistant TB survivors unite behind ZERO TB and
ZERO STIGMA on South African National Women’s Day. Left to right: Nurse Patricia
Bond, Nurse Jolene Samuels, Dr Thato Mosidi and Dr Dalene von Delft.  TB Proof.
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result in preventable suffering and loss of life. Just as Ebola has
caused mass panic and an exodus of HCWs from affected countries,
the mounting prospect of incurable forms of DR-TB may further
worsen loss through emigration of HCWs from high-burden TB
countries.
TB is preventable and, in the majority of cases, is curable. But
the reality is that HCWs are not safe, and that means neither are
those under their care. We cannot afford, either economically or
socially, to wait for the DR-TB situation to deteriorate further.
Urgent action is required to improve TB IC implementation and to
ensure equal access to better treatment for all. HCWs are on the
front lines of care – and on the front lines of risk. We must also be
on the front lines of change. Photo 1
As HCWs we are sick of TB: sick of the ineffectual global
response to TB and DR-TB control and sick of the lack of
infrastructure and resources to prevent transmission from patients
to HCWs. Everything possible should be done to protect and retain
the HCW resource through active interventions to reduce the risk
of occupational TB. All HCWs should stand together to lobby
healthcare policymakers, managers, and colleagues to create safer
working conditions in all healthcare facilities, but especially those
in high-burden TB settings.
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